medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 5

<< Back Next >>

Ann Hepatol 2018; 17 (5)

Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients

Giannini EG, Giambruno E, Brunacci M, Plaz TMC, Furnari M, Bodini G, Zentilin P, Savarino V

Language: English
References: 31
Page: 830-835
PDF size: 144.41 Kb.


ABSTRACT

Introduction and Aim. EVBL is a procedure frequently performed in cirrhotic patients for primary prophylaxis of bleeding. Patients with cirrhosis display various degrees of alteration of common coagulation parameters, and it is not known whether these alterations may predict post-EVBL bleeding. To evaluate factors predictive of post-endoscopic variceal band ligation (EVBL) bleeding in cirrhotic patients with thrombocytopenia. Material and methods. We included 109 patients with cirrhosis undergoing EVBL for primary prophylaxis of variceal bleeding. Common coagulation parameters (INR, fibrinogen levels) and complete haemogram were obtained in all patients and evaluated subdividing patients in bleeders and non bleeders following EVBL. Results. The incidence of post-EVBL bleeding was 5.5% (6 patients). INR and platelet counts, considered as continuous or dichotomous variables according to common cut-offs (i.e., INR › 1.5, platelet count ‹ 50 x 109/L) were not predictors of post-EVBL bleeding. Patients who bled had significantly lower fibrinogen levels [146 mg/dL (98 - 262) vs. 230 mg/dL (104 - 638), P = 0.009], and no other biochemical or clinical predictors of bleeding were identified. A fibrinogen cut-off of 179 mg/dL had 98.6% negative predictive value for bleeding. Conclusion. Low fibrinogen levels are associated with an increased risk of bleeding following prophylactic EVBL in cirrhotic patients, and might be used to stratify patients' risk. However, due to their preliminary nature, these findings need to be confirmed in larger populations.


REFERENCES

  1. Giannini E, Botta F, Borro P, Risso D, Romagnoli P, Fasoli A, Mele MR, et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 2003; 52: 1200-5.

  2. Giannini EG, Risso D, Testa R, Trevisani F, Di Nolfo MA, Del Poggio P, Benvegnù L, et al. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4: 1378-84.

  3. Burton JR Jr, Liangpunsakul S, Lapidus J, Giannini E, Chalasani N, Zaman A. Validation of a multivariate model predicting presence and size of varices. J Clin Gastroenterol 2007; 41: 609-15.

  4. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey WD; Practice Guidelines Committee of American Association for Study of Liver Diseases; Practice Parameters Committee of American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol 2007; 102: 2086-02.

  5. Thalheimer U, Bosch J, Burroughs AK. How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers. Gastroenterology 2007; 133: 2029-36.

  6. Thalheimer U, Christie J, Burroughs AK. Benefits of Beta blockade beyond bleeding prophylaxis and the role of adherence. Am J Gastroenterol 2012; 107: 1593.

  7. Garcia-Pagan JC. Non-selective beta-blockers in the prevention of first variceal bleeding. Is there any definite alternative? J Hepatol 2002; 37: 393-5.

  8. Aguilar-Olivos N, Motola-Kuba M, Candia R, Arrese M, Méndez- Sánchez N, Uribe M, Chávez-Tapia NC. Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis. Ann Hepatol 2014; 13: 420-8.

  9. Sersté T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, Moreau R, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52: 1017-22.

  10. Sersté T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, Moreau R, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol 2011; 55: 794-9.

  11. Moctezuma-Velazquez C, Kalainy S, Abraldes JG. Betablockers in patients with advanced liver disease: Has the dust settled? Liver Transpl 2017; 23: 1058-69.

  12. Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol 2008; 15: 473-80.

  13. Giannini EG, Greco A, Marenco S, Andorno E, Valente U, Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol 2010; 8: 899-902.

  14. Shah NL, Northup PG, Caldwell SH. A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients. Ann Hepatol 2012; 11: 686-90.

  15. Vieira da Rocha EC, D'Amico EA, Caldwell SH, Flores da Rocha TR, Soares E, Silva CS, Dos Santos Bomfim V, et al. A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation. Clin Gastroenterol Hepatol 2009; 7: 988-93.

  16. Muciño-Bermejo J, Carrillo-Esper R, Méndez-Sánchez N, Uribe M. Thrombosis and hemorrhage in the critically ill cirrhotic patients: five years retrospective prevalence study. Ann Hepatol 2015; 14: 93-8.

  17. Stephen SC, Nicolas NC, The CI. A Summary of The 6th International Conference on Coagulation in Liver Disease: Discussion, Debate, Deliberations. Ann Hepatol 2017; 16: 12-5.

  18. Giannini EG. Platelet count manipulation and modification of global haemostasis tests in patients with chronic liver disease: almost there, almost there… Liver Int 2013; 33: 325-6.

  19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.

  20. Giannini E, Botta F, Testa E, Romagnoli P, Polegato S, Malfatti F, Fumagalli A, et al. The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. Am J Gastroenterol 2002; 97: 2855-60.

  21. Lim EJ, Gow PJ, Angus PW. Endoscopic variceal ligation for primary prophylaxis of esophageal variceal hemorrhage in pre-liver transplant patients. Liver Transpl 2009; 15: 1508- 13.

  22. Vanbiervliet G, Giudicelli-Bornard S, Piche T, Berthier F, Gelsi E, Filippi J, Anty R, et al. Predictive factors of bleeding related to post-banding ulcer following endoscopic variceal ligation in cirrhotic patients: a case-control study. Aliment Pharmacol Ther 2010; 32: 225-32.

  23. Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Dig Liver Dis 2016; 48: 455-67.

  24. Escolar G, Cases A, Viñas M, Pino M, Calls J, Cirera I, Ordinas A. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999; 84: 614-9.

  25. Liu TT, Wong WJ, Hou MC, Lin HC, Chang FY, Lee SD. Hemorheology in patients with liver cirrhosis: Special emphasis on its relation to severity of esophageal variceal bleeding. J Gastroenterol Hepatol 2006; 21: 908-13.

  26. Green G, Poller L, Thomson JM, Dymock IW. Association of abnormal fibrin polymerisation with severe liver disease. Gut 1977; 18: 909-12.

  27. Violi F, Leo R, Vezza E, Basili S, Cordova C, Balsano F. Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. C.A.L.C. Group. Coagulation Abnormalities in Cirrhosis Study Group. J Hepatol 1994; 20: 531-6.

  28. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, Nieuwenhuis HK, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-9.

  29. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38: 230-7.

  30. Landolfi R, De Cristofaro R, De Candia E, Rocca B, Bizzi B. Effect of fibrinogen concentration on the velocity of platelet aggregation. Blood 1991; 78: 377-81.

  31. DeAngelis GA, Khot R, Haskal ZJ, Maitland HS, Northup PG, Shah NL, Caldwell SH. Bleeding risk and management in interventional procedures in chronic liver disease. J Vasc Interv Radiol 2016; 27: 1665-74.




2020     |     www.medigraphic.com